Graft failure is a life-threatening complication that occasionally occurs following hematopoietic stem cell transplantation (HSCT). The incidence of graft failure following allogeneic HSCT is below 5%. 1 Risk factors include donor-recipient HLA or ABO mismatch, unrelated donor, less intense conditioning regimen, T-cell depletion, insufficient number of transplanted stem cells, and viral infections such as cytomegalovirus infection. 1 Over the past several years, cord blood transplantation (CBT) has been increasingly performed for the treatment of adult hematological malignant diseases. [2] [3] [4] [5] The advantages of CBT include prompt availability and less stringent requirement of HLA identity between donor and recipient because of the low risk of GVHD. However, CBT has been associated with delays in neutrophil and platelet recovery. 5, 6 In previous studies, myeloid engraftment was achieved in 74-90% of adult patients who underwent CBT. 4, 5 However, there are few data on the management of graft failure after CBT as CBT is a relatively new procedure.
Here, we report a patient with graft failure following CBT for AML who was successfully treated with a second CBT with reduced-intensity conditioning (RIC).
A 16-year-old Japanese girl was diagnosed with AML (FAB: M0) with trisomy 4 in January 2002. She failed to achieve remission with the first three courses of induction chemotherapy, and finally reached CR after the fourth course of chemotherapy in May 2002. Due to the lack of a suitable donor candidate among family members and unrelated donors, CBT was planned and she was referred to our hospital in August 2002. The conditioning regimen consisted of CY, 60 mg/kg once daily i.v. on days À5 and À4 (total dose 120 mg/kg), and TBI of 12 Gy in six fractions from days À3 to À1. She received an infusion of serologically two HLA-loci mismatched unrelated cord blood containing 2.27 Â 10 7 nucleated cells/kg in September 2002. CsA and short-term MTX were administered for prophylaxis against GVHD. G-CSF was administered from day 5. However, hematological recovery was not observed up through day 30. The BM sample on day 31 revealed severely hypocellular marrow with complete recipient chimerism, indicating primary graft failure and insufficient autologous recovery. Despite being strongly myelosuppressed and transfusion-dependent, there were no signs of active infection or organ damage. She had positive CMV serology prior to the transplant, although there had been no signs of active CMV infection. In view of her good general condition and the high risk of disease recurrence, a second CBT was planned for October 2002.
Due to the high risk of regimen-related toxicity (RRT), a RIC regimen was selected for the second transplant. The conditioning regimen consisted of fludarabine (Flu), 25 mg/kg once daily i.v. from days À6 to À2 (total dose 125 mg/kg); busulfan, 4 mg/kg p.o. on days À5 and -4 (total dose 8 mg/kg); and rabbit antithymocyte globulin (ATG), 15 mg/kg once daily i.v. on days À3 and À2 (total dose 30 mg/kg). CsA had been discontinued before conditioning, and tacrolimus 0.025 mg/kg was started on day À1 for GVHD prophylaxis. On day 43 of the initial transplant, serologically three HLA-loci mismatched cord blood containing 4.42 Â 10 7 /kg nucleated cells was transplanted. Detailed information on the first and second cord blood units is summarized in Table 1 . G-CSF had been discontinued before conditioning for the second CBT, and after the second CBT, G-CSF was administered from day 5 to day 21, at which point her ANC rose above 500/mm 3 and engraftment was achieved. The BM sample obtained on day 21 showed complete donor chimerism. She developed de novo type extensive chronic GVHD with mild liver damage and sicca syndrome. She remains in CR 19 months after the second CBT, but currently suffers from refractory CMV retinitis.
Management of graft failure after HSCT includes augmentation by growth factors, administration of additional or 'booster' hematopoietic stem cells (HSC), and second transplantation with pre-infusion conditioning. 1 BM or PBSC from the original donor or another donor may serve as the additional HSC. There have been several retrospective studies on patients who underwent a second BMT or PBSCT for the treatment of graft failure. 7, 8 Among 82 patients with acute leukemia, aplastic anemia, or chronic myeloid leukemia who underwent a second transplant, the engraftment rate was 73% with a median intertransplant time interval of 62 days and a day-100 transplant-related mortality (TRM) of 50%. 8 The efficacy of a second transplant after initial BMT has been shown; however, the best source of HSCs remains unclear. 9 Considering the potential advantages of prompt availability and less stringent requirement for HLA identity, as well as the safety and efficacy of CBT in adult patients, the use of cord blood would allow the second transplant to be performed at an optimal time in the clinical course of the patient and is feasible as a source of HSC for second transplant following graft failure. 4 Studies on the effectiveness of a second CBT for graft failure following CBT are also needed.
In two previous studies, among patients who underwent a second HSCT, high TRM and a high rate of RRT were observed, and a longer intertransplant time interval was associated with a better outcome. 8, 9 However, among patients with graft failure, prolonged myelosuppression increases the risk of infectious complications and the number of blood transfusions. The RIC regimen provides an opportunity for stem cell transplantation in high-risk adults; moreover, the usefulness of the RIC regimen was recently studied in patients who underwent CBT. 10 In patients who underwent CBT, the cumulative incidence of donor engraftment was 76% among BU/Flu/TBI recipients and 94% among CY/Flu/TBI recipients, 10 the latter of which was higher than that among patients who underwent myeloablative CBT. [3] [4] [5] [6] In our patient, although the first 2-HLA-loci mismatched cord blood was rejected despite a sufficient cells, the second 3-HLA-loci mismatched cord blood successfully engrafted. The number of cells infused in the second transplant was nearly twice as high as that in the initial CBT, which may have played a role in the successful engraftment. To avoid graft rejection, ATG was used as part of the RIC regimen for the second CBT. However, the use of ATG may increase the risk for viral infection after transplantation and the patient developed severe CMV retinitis after the second CBT. Whether the use of ATG significantly contributes to the success of second CBT should be studied further. The present case suggests that the RIC regimen renders a second CBT a feasible therapeutic option for patients with graft failure who are not eligible for early second transplantation with myeloablative conditioning and where there is no suitable BM or PBSC donor. This is the first report of a patient with graft failure after CBT who was successfully treated with a second CBT with a RIC regimen. Table 1 Characteristics of the patient and the cord blood units used in the first and second CBTs 
